论文部分内容阅读
罗格列酮[商品名为文迪雅(Avandia)]为噻唑烷二酮类降糖药,能提高胰岛素敏感性,用于治疗2型糖尿病。该药于1999年6月在美国上市,2000年在中国上市。2007年5月Nissen等[1]在《新英格兰医学杂志》上发表了一篇有关罗格列酮安全性的荟萃分析报告,认为罗格列酮能增加心肌梗死和心血
Rosiglitazone [trade name Avandia] is a thiazolidinedione-lowering hypoglycemic agent that increases insulin sensitivity for the treatment of type 2 diabetes. The drug was listed in the United States in June 1999 and in China in 2000. May 2007 Nissen et al [1] in the New England Journal of Medicine published a meta-analysis of the safety of rosiglitazone report that rosiglitazone can increase myocardial infarction and effort